A study in a murine model overexpressing human APOE4, with increased Aβ1–42 burden and cognitive impairment, lower plasma EGF was also reported, and EGF treatment was shown to alleviate cognitive decline, reduce microbleeds and increase cerebrovascular coverage [93,94]. The gene discussed is APOE; the disease is Cognitive impairment.